Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia.
Costa A, Gurnari C, Scalzulli E, Cicconi L, Guarnera L, Carmosino I, Cerretti R, Bisegna ML, Capria S, Minotti C, Iori AP, Torrieri L, Venditti A, Pulsoni A, Martelli M, Voso MT, Breccia M. Costa A, et al. Among authors: scalzulli e. Cancers (Basel). 2024 Sep 21;16(18):3214. doi: 10.3390/cancers16183214. Cancers (Basel). 2024. PMID: 39335185 Free PMC article.
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
Cicconi L, Bisegna M, Gurnari C, Fanciullo D, Piciocchi A, Marsili G, Minotti C, Scalzulli E, Mandelli B, Guarnera L, Perrone S, Ortu La Barbera E, Mecarocci S, Biagi A, Cenfra N, Corbingi A, Scerpa MC, Venditti A, Martelli M, Voso MT, Breccia M, Pulsoni A. Cicconi L, et al. Among authors: scalzulli e. Br J Haematol. 2024 Nov;205(5):1727-1733. doi: 10.1111/bjh.19759. Epub 2024 Sep 14. Br J Haematol. 2024. PMID: 39275865
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Among authors: scalzulli e. Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30. Cancer. 2024. PMID: 39078647 Free PMC article.
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
Laganà A, Scalzulli E, Bisegna ML, Carmosino I, Ielo C, Costa A, Torrieri L, Totaro M, Martelli M, Breccia M. Laganà A, et al. Among authors: scalzulli e. Expert Opin Drug Saf. 2024 Aug;23(8):969-979. doi: 10.1080/14740338.2024.2368822. Epub 2024 Jun 17. Expert Opin Drug Saf. 2024. PMID: 38873693 Review.
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, Scalzulli E, Morgades M, Senín A, Hernández-Boluda JC, Ferrer-Marín F, Anguita E, Cortés M, Plensa E, Breccia M, García-Gutierrez V, Zamora L; Grupo Español de Leucemia Mieloide Crónica (GELMC). Marcé S, et al. Among authors: scalzulli e. J Clin Med. 2024 Jan 29;13(3):779. doi: 10.3390/jcm13030779. J Clin Med. 2024. PMID: 38337473 Free PMC article.
78 results